[Form 4] Monopar Therapeutics Insider Trading Activity

Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) insiders reported a significant sale of common stock by an affiliated investor group on 09/24/2025. Tactic Pharma LLC sold 550,229 shares at a reported price of $63.6098 per share, leaving beneficial ownership of 272,026 shares following the transaction. The Form 4 is filed on behalf of Tactic and its managers—Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran—who collectively have voting control over the disclosed shares but disclaim ownership except for any pecuniary interest. Chandler D. Robinson remains subject to Section 16 reporting as CEO.

Positive

• Timely SEC disclosure of the insider transaction by Tactic Pharma LLC and named managers
• Clear identification of reporting persons and their roles, including CEO Chandler D. Robinson

Negative

• Large disposition of 550,229 common shares on 09/24/2025 at $63.6098 may indicate insider liquidity
• Post-transaction beneficial ownership reduced to 272,026 shares for the reporting entity

Insights

Financial Analyst

TL;DR: A large insider sale was disclosed; this is a material transfer of shares but the filing provides no reason or market context.

The report shows a dispositional transaction of 550,229 common shares at $63.6098 on 09/24/2025, reducing beneficial holdings to 272,026 shares held indirectly by Tactic Pharma LLC. For valuation impact, the filing gives the executed price but lacks context such as total outstanding shares, timing rationale, or whether the sale was part of a planned program. The disclosure is useful for holders tracking insider liquidity but does not by itself indicate company operational changes or governance actions.

Corporate Governance Expert

TL;DR: Managers jointly control the sold shares; the filing discloses voting control and disclaimers, but provides no governance change.

The Form 4 is filed on behalf of Tactic Pharma LLC and its four managers, who state collective voting control and disclaim direct ownership aside from pecuniary interests. Chandler D. Robinson is separately identified as still subject to Section 16 reporting due to his CEO role. The filing documents proper reporting of a sizeable disposition but does not indicate any change in board composition, management roles, or control arrangements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tactic Pharma LLC

(Last) (First) (Middle)

C/O 598 ROCKEFELLER RD

(Street)

LAKE FOREST IL 60045

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2025		S		550,229	D	$63.6098	272,026	D(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Tactic Pharma LLC

(Last) (First) (Middle)

C/O 598 ROCKEFELLER RD

(Street)

LAKE FOREST IL 60045

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Robinson Chandler

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE IL 60091

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

1. Name and Address of Reporting Person^*

Brown Michael J

(Last) (First) (Middle)

C/O 598 ROCKEFELLER RD

(Street)

LAKE FOREST IL 60045

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Member of 10% Owner Group

1. Name and Address of Reporting Person^*

O'Halloran Thomas V.

(Last) (First) (Middle)

C/O 598 ROCKEFELLER RD

(Street)

LAKE FOREST IL 60045

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Member of 10% Owner Group

1. Name and Address of Reporting Person^*

Mazar Andrew Paul

(Last) (First) (Middle)

C/O 598 ROCKEFELLER RD

(Street)

LAKE FOREST IL 60045

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Member of 10% Owner Group

Explanation of Responses:

1. This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc.

	/s/ Chandler Robinson, Attorney-in-fact	09/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Monopar Therapeutics (MNPR) report on Form 4?

The Form 4 reports that Tactic Pharma LLC disposed of 550,229 shares of Monopar common stock on 09/24/2025 at a price of $63.6098 per share.

How many Monopar shares does Tactic Pharma LLC beneficially own after the sale?

Following the reported transaction, Tactic Pharma LLC beneficially owns 272,026 shares according to the Form 4.

Who are the reporting persons named in the Form 4 for MNPR?

The filing is on behalf of Tactic Pharma LLC and its managers: Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran.

Is any reporting person still subject to Section 16 reporting obligations?

Yes. The filing states the Reporting Persons are no longer subject to Section 16 except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics.

Does the Form 4 explain why the shares were sold?

No. The Form 4 discloses the sale and amounts but does not provide a reason or context for the disposition.